ILMN News & Events

Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. By connecting IDT's library prep with Illumina's DRAGEN secondary analysis platform, researchers can reduce downstream burden and accelerate the path from sequencing to insight with greater speed and consistency. IDT's xGen FFPE and cfDNA workflows already support hundreds of thousands of samples annually, and this collaboration is designed to reduce the NGS analysis burden by streamlining the journey from sample to insights for oncology researchers. The DRAGEN Somatic for IDT Custom Panels was designed for use with IDT library prep workflows and optimized for challenging FFPE samples with a new, low-quality FFPE mode. This integrated workflow ensures that researchers can collect more reliable insights from degraded oncology research samples.

Illumina announced a new complete solution for molecular residual disease research based on whole-genome sequencing. As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer genomic profiling. It is the first in a new portfolio of WGS oncology research offerings, with additional solutions in development leveraging the latest advancements of the NovaSeq X.

Illumina (ILMN) confirmed the election of David King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. . King is the former Executive Chairman and Chief Executive Officer of Labcorp (LH).